Validity of the Mindstreams™ computerized cognitive battery for mild cognitive impairment
Source: Journal of Molecular Neuroscience, Volume 24, Number 1, February 2004 , pp. 33-44(12)
Publisher: Humana Press
Abstract:The NeuroTrax Mindstreams™ computerized cognitive assessment system was designed for widespread clinical and research use in detecting mild cognitive impairment (MCI). However, the capability of Mindstreams tests to discriminate the elderly with MCI from those who are cognitively healthy has yet to be evaluated. Moreover, the comparability between these tests and traditional neuropsychological tests in detecting MCI has not been examined. A two-center study was designed to assess the discriminant validity of tests in the Mindstreams Mild Impairment Battery. Participants were 30 individuals diagnosed with MCI, 29 with mild Alzheimer’s disease (AD), and 39 healthy elderly. Testing was with the Mindstreams battery and traditional neuropsychological tests. Receiver operating characteristic (ROC) analysis was used to examine the ability of Mindstreams and traditional measures to discriminate those with MCI from cognitively healthy elderly. Between-group comparisons were made (Mann-Whitney U test) between MCI and healthy elderly and between MCI and mild AD groups. Mindstreams outcome parameters across multiple cognitive domains significantly discriminated between MCI and healthy elders with considerable effect sizes (p<0.05). Measures of memory, executive function, visual spatial skills, and verbal fluency discriminated best, and discriminability was at least comparable to that of traditional neuropsychological tests in these domains. Mindstreams tests are effective in detecting MCI, providing a comprehensive profile of cognitive function. Further, the enhanced precision and ease of use of these computerized tests make the NeuroTrax system a valuable clinical tool in the identification of elders at high risk for dementia.
Document Type: Research Article
Affiliations: 1: Memory Disorders Clinic and Department of Geriatrics, Shaare Zedek Medical Center, Jerusalem, Israel, 2: Department of Clinical Neurosciences, McGill University, Montreal, Canada, 3: Department of Clinical Science, NeuroTrax Corporation, New York, NY, 4: Department of Behavioral Sciences, Academic College of Tel Aviv, Tel Aviv, Israel, 5: School of Public Health, Hebrew University-Hadassah Medical School, Jerusalem, Israel, 6: Department of Clinical Neurosciences, McGill University, Montreal, Canada, Email: email@example.com
Publication date: February 1, 2004